ANSCUMEDIUM SIGNALFINANCIAL10-K

ANSCU shows improved operating performance but deteriorating balance sheet health with substantially higher current liabilities and deepening negative equity position.

The company's operational efficiency appears to be improving with reduced operating losses and higher net income, suggesting better cost management or revenue performance. However, the substantial increase in current liabilities alongside declining current assets raises concerns about near-term liquidity and working capital management that investors should monitor closely.

Comparing 2026-03-27 vs 2025-03-28View on EDGAR →
FINANCIAL ANALYSIS

The financial picture presents mixed signals with operational improvements offsetting balance sheet deterioration. While operating losses narrowed meaningfully and net income grew modestly, the company's financial position weakened significantly with current liabilities increasing 63.9% to $17.3M and stockholders equity becoming more negative at -$29.2M. The combination of higher liabilities and reduced current assets suggests potential working capital pressures that could impact the sustainability of the improved operational performance.

FINANCIAL STATEMENT CHANGES
Current Liabilities
Balance Sheet
+63.9%
$10.6M$17.3M

Current liabilities surged 63.9% — significant near-term obligations; verify ability to meet short-term debt.

Operating Income
P&L
+46.3%
-$10.2M-$5.5M

Operating leverage kicking in — revenue growth outpacing cost growth, a hallmark of scaling businesses.

Stockholders Equity
Balance Sheet
-30.5%
-$22.4M-$29.2M

Equity declined sharply — large losses, buybacks, or write-downs reducing book value significantly.

Total Liabilities
Balance Sheet
+29.8%
$22.6M$29.4M

Liabilities increased 29.8% — monitor debt-to-equity ratio and interest coverage.

Net Income
P&L
+25.2%
$8.4M$10.5M

Net income grew 25.2% — bottom-line growth signals improving overall business health.

Current Assets
Balance Sheet
-21.5%
$273K$215K

Current assets declined 21.5% — monitor working capital adequacy and short-term liquidity.

LANGUAGE CHANGES
NEW — 2026-03-27
PRIOR — 2025-03-28
ADDED
As of March 27, 2026, 32,922,237 Class A ordinary shares, par value $0.0001 per share, and 8,625,000 Class B ordinary shares, par value $0.0001 per share, were issued and outstanding.
The firm maintains offices in New York, Mexico City and Amsterdam.
On March 25, 2026, the last reported sale price of Permian s common stock on the NYSE was $20.68 per share.
Tepper, and other defendants have reached settlements, and a motion for preliminary approval was filed on January 6, 2025.
The court held a final approval hearing on April 30, 2025, and it granted final approval to the settlements and entered a final judgment and order of dismissal with prejudice on May 6, 2025.
+7 more — sign up free →
REMOVED
As of March 28, 2025, 34,500,000 Class A ordinary shares, par value $0.0001 per share, and 8,625,000 Class B ordinary shares, par value $0.0001 per share, were issued and outstanding.
Our Sponsor agreed to, subject to, and conditioned upon the Business Combination Closing (as defined below), waive the anti-dilution rights set forth in our amended and restated memorandum and articles of association with respect to the Founder Shares held by it.
Business Proposed Business Combination Sponsor Support Agreement.
The firm maintains offices in New York, London, Houston, Mexico City and Amsterdam.
On March 25, 2025, the last reported sale price of Permian s common stock on the NYSE was $14.25 per share.
+7 more — sign up free →
MORE FINANCIAL SIGNALS
CRMHIGHSalesforce significantly increased debt by 71% to $14.4B while simultaneously ac...
2026-03-02
UNHHIGHUNH's operating income plummeted 41% despite 12% revenue growth, indicating seve...
2026-03-02
PFEHIGHPfizer achieved a dramatic 87.3% reduction in total debt from $31.4B to $4.0B, r...
2026-02-26
GILDHIGHGILD dramatically increased R&D spending by 81.5% to $9.1B while introducing new...
2026-02-24
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →